Our Pricing

Finding the lowest cost weight loss injections UK pharmacies offer doesn't mean compromising on quality or clinical support. At Cured Pharmacy, we provide genuine UK-licensed weight loss treatments including Mounjaro, Wegovy, and Saxenda with transparent upfront pricing from £135.00 free clinical consultations under three minutes, and dispensing by our UK-registered clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

How Weight Loss Injections Work: GLP-1 Receptor Agonists Explained

Weight loss injections available in the UK belong to a class of medications called GLP-1 receptor agonists, which mimic naturally occurring hormones that regulate appetite and blood sugar control [1]. These medications work by slowing gastric emptying, reducing hunger signals to the brain, and improving insulin sensitivity—mechanisms that together support significant weight reduction when combined with lifestyle modifications.

The most advanced option, Mounjaro (tirzepatide), represents a breakthrough as the first dual GIP/GLP-1 receptor agonist licensed by the MHRA [2]. By activating two complementary hormonal pathways rather than one, tirzepatide demonstrated superior weight loss outcomes in clinical trials. In the SURMOUNT-1 trial, participants achieved an average body weight reduction of up to 22.5% over 72 weeks at the highest dose—substantially greater than single-pathway alternatives [2].

Wegovy (semaglutide) and Saxenda (liraglutide) are established GLP-1 receptor agonists with robust clinical evidence. The STEP 1 trial showed semaglutide produced average weight loss of 14.9% over 68 weeks, whilst liraglutide achieved approximately 8% reduction in the SCALE trial [1][3]. All three medications require prescription following clinical assessment by a UK-registered prescriber, as individual suitability depends on medical history, current medications, and weight management goals.

Lowest Cost Weight Loss Injections UK: Transparent Pricing Breakdown

At Cured Pharmacy, weight loss injection pricing starts from £135.00 for Mounjaro, making genuine UK-licensed treatment accessible without hidden consultation fees or membership charges. Unlike many online providers, we display exact pricing before you complete your clinical assessment, ensuring complete transparency throughout the process.

Your final cost depends on the prescribed dose and treatment duration determined by your UK prescriber during the free online consultation. Mounjaro is available in escalating doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg), with dosing titrated gradually over 16-20 weeks to minimise side effects whilst optimising weight loss outcomes. Our pharmacist team dispenses only the dose approved by your prescriber, ensuring clinical safety remains paramount.

We guarantee the lowest prices in the UK market for genuine, MHRA-licensed weight loss medications. Every pen is sourced directly from licensed UK wholesalers and stored in our GPhC-registered pharmacy premises (registration number 9012511), maintaining the cold chain integrity essential for these temperature-sensitive biologics.

What's Included in Your Treatment Cost

Your weight loss injection price includes free clinical consultation with a UK-registered prescriber, dispensing by our qualified pharmacy team, discreet packaging with no external branding, and tracked delivery to your chosen address. There are no hidden fees, subscription charges, or mandatory follow-up costs—you pay only for the medication prescribed following your clinical assessment.

Mounjaro vs Wegovy vs Saxenda: Choosing the Right Treatment

Selecting between weight loss injections depends on clinical factors including your BMI, previous treatment response, injection frequency preference, and budget considerations. Mounjaro offers the highest average weight reduction in clinical trials but requires weekly subcutaneous injections [2]. Wegovy also follows a once-weekly schedule and has extensive real-world safety data from its earlier approval [1].

Saxenda differs by requiring daily injections, which some patients find more manageable for maintaining routine adherence, though clinical trial data shows more modest average weight loss compared to newer dual-agonist treatments [3]. Your UK prescriber will assess which medication aligns with your medical profile, lifestyle factors, and weight management objectives during the online consultation.

All three medications are licensed by the MHRA specifically for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidaemia. Clinical guidelines from NICE emphasise these treatments should complement—not replace—dietary changes and increased physical activity for sustainable outcomes.

Injection Frequency and Administration

Mounjaro and Wegovy require one subcutaneous injection per week, administered using a pre-filled pen device into the abdomen, thigh, or upper arm. Saxenda requires daily injections at the same time each day. All three medications come with detailed patient information leaflets and injection technique guidance. Our pharmacy team can provide additional administration support if needed following your prescription approval.

Clinical Evidence: What the Trials Show for Weight Loss Outcomes

The SURMOUNT-1 trial, published in the New England Journal of Medicine, demonstrated tirzepatide's exceptional efficacy with 89% of participants achieving at least 5% body weight reduction—the threshold considered clinically meaningful—and 57% achieving 20% or greater reduction at the 15mg dose [2]. These results represent the highest weight loss outcomes achieved by any medication-based intervention in randomised controlled trials to date.

Semaglutide's pivotal STEP trials showed consistent weight reduction across diverse populations. In STEP 1, participants without diabetes achieved average weight loss of 14.9% versus 2.4% with placebo over 68 weeks [1]. The STEP 2 trial, which included participants with type 2 diabetes, showed average reduction of 9.6% with semaglutide 2.4mg weekly [4].

Liraglutide's SCALE Obesity and Prediabetes trial demonstrated average weight loss of 8.0% versus 2.6% with placebo over 56 weeks, with 63.2% of participants achieving at least 5% weight reduction [3]. Whilst more modest than newer agents, liraglutide has the longest real-world safety record among GLP-1 treatments for weight management, having been available since 2015.

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most frequently reported adverse events with GLP-1 receptor agonists, affecting approximately 40-50% of users in clinical trials [1][2]. Nausea, diarrhoea, constipation, and abdominal discomfort typically emerge during dose escalation and diminish over 4-8 weeks as the body adapts to the medication.

Clinical strategies to minimise side effects include gradual dose titration (the reason all three medications start at lower doses), eating smaller portions more frequently, avoiding high-fat meals which delay gastric emptying further, and maintaining adequate hydration. Your prescriber will provide specific guidance on managing side effects based on your individual response during treatment.

Serious adverse events are rare but include potential pancreatitis, gallbladder disease, and hypoglycaemia particularly in patients taking concurrent diabetes medications [2][4]. All weight loss injections carry a contraindication in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will screen for these contraindications during your clinical assessment before approving any prescription.

When to Contact Your Prescriber

Seek immediate medical advice if you experience severe persistent abdominal pain (potential pancreatitis), signs of allergic reaction including facial swelling or difficulty breathing, rapid heartbeat, or symptoms of hypoglycaemia such as confusion, sweating, or tremors. Most side effects are mild and self-limiting, but your prescriber can adjust dosing or recommend alternative treatments if adverse effects significantly impact your quality of life.

How to Order Weight Loss Injections from Cured Pharmacy

Ordering weight loss injections through Cured Pharmacy takes under three minutes via our secure online consultation platform. You'll complete a clinical questionnaire covering your medical history, current medications, weight management goals, and any contraindications. A UK-registered prescriber reviews your assessment within hours, typically the same working day.

If your prescriber approves treatment, your prescription is sent electronically to our GPhC-registered pharmacy where our team dispenses your medication in accordance with MHRA guidelines. We dispatch weight loss injections in temperature-controlled packaging with ice packs to maintain the 2-8°C storage requirement throughout transit, using tracked courier services for delivery within 24-48 hours to most UK addresses.

All weight loss medications are supplied in 100% discreet packaging with no external indication of contents or pharmacy branding. Your privacy is protected at every stage, from encrypted online consultation to unmarked delivery packaging. Prescription medications require clinical approval—our prescribers may recommend alternative treatments or suggest GP consultation if weight loss injections are not clinically appropriate based on your individual assessment.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., Wilding, J. P. H., & SCALE Obesity and Prediabetes NN8022-1839 Study Group. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., Lingvay, I., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to diet and exercise recommendations alongside medication use.